Of note, 122/224 (54%) of group 1 enhancers were also co-occupied by FOXC1 and RUNX1 in primary AML cells (BB171) with strong binding close to genes such as KLF2, ID1, and MEF2C (Figures 4A and S5E). This evidence concerns the gene RUNX1 and acute myeloid leukemia.